News and Announcements
Second Patient In Human Cancer Trial Begins Treatment
- Published November 24, 2014 2:54PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Source: ASX; Published: 24 November 2014
PharmAust Limited (ASX:PAA & PAA)) is pleased to report that it has initiated treatment of the second patient on 21 November 2014 in its ‘First in Man’ trial with PPL-1. To date the drug appears safe and no adverse events have been observed. The patient will receive PPL-1 daily for 28 days. The patient is suffering from lung cancer with metastases to other organs.
PharmAust’s Executive Chairmna Dr Roger Aston said “In addition to the second patient referred above, a further two patients have entered screening and, subject to their suitability, will be recruited and also begin treatment on 2 and 9 December respectively’.
Please download the document below to view the full announcement.